April 24, 2025

W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute

Former Director of NCI, Dr. W. Kimryn Rathmell, renowned for cancer research, appointed CEO of The Ohio State University Comprehensive Cancer Center, promising visionary leadership and a commitment to health equity.

The ASCO Post

April 24, 2025

FDA Expands Indication for Lu-177 Vipivotide Tetraxetan in mCRPC

The indication for lutetium Lu-177 vipivotide tetraxetan (Pluvicto) was expanded by the FDA to include adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been t...

The ASCO Post

April 24, 2025

Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal Cancer

Current standard chemoradiation therapy remains the most effective treatment for selected patients with human papillomavirus (HPV)-positive oropharyngeal cancer, based on the results of the NRG-HN005 ...

The ASCO Post

April 24, 2025

Pembrolizumab Plus Chemotherapy: New Standard of Care in Locally Advanced Cervical Cancer?

Updated findings from the second planned interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study solidify the PD-1 inhibitor pembrolizumab plus concurrent chemoradiotherapy, followed b...

The ASCO Post

April 24, 2025

Executive Orders and Cancer Care

The Association for Clinical Oncology (ASCO) is working to understand the extent and scope of several recent executive actions. ASCO recognizes the concern and confusion many are currently experiencin...

The ASCO Post

April 24, 2025

FDA Approves Perioperative Durvalumab for Muscle-Invasive Bladder Cancer

The FDA has approved the PD-L1 inhibitor durvalumab (Imfinzi) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cyste...

The ASCO Post

April 24, 2025

Cabozantinib Approved for Treatment of Neuroendocrine Tumors

The U.S. Food and Drug Administration (FDA) recently approved the tyrosine kinase inhibitor cabozantinib (Cabometyx) for adult and pediatric patients aged 12 years and older with previously treated, ...

The ASCO Post

April 24, 2025

Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer

Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PAR...

The ASCO Post

April 23, 2025

Polygenic Risk Score for Prostate Cancer Screening

In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al  found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than scree...

The ASCO Post